Tsakos Energy Navigation Limited logo

Tsakos Energy Navigation Limited

TEN | NYSE
Chart Builder DCF Calculator
$52.71
-$1.14 (-2.12%)
Nov 2, 2026, 9:32 AM ET · Market open
-2.12%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 2, 2026
75.3
+23.0 pts
Fundamentals Excellent
Market Sentiment Bullish
Moat Narrow
Sector Rank #28/302 (Top 9%)

Key Statistics

Market Data

Market Cap $1.59B
1D Range
52.71 52.71
52W Range
21.71 56.40

Valuation (TTM)

PE 5.45
PB 0.79
EV/EBITDA 6.93

Valuation (NTM)

Forward PE 4.17
Forward PEG 0.02
Price Target $65.00
Loading financial charts...

Profile

Tsakos Energy Navigation Limited (TEN) is a global maritime company dedicated to the worldwide ocean transport of crude oil and refined petroleum products. The firm delivers vital shipping and logisti...

Sector Energy
Employees 77
IPO Date Mar 5, 2002
Website www.tenn.gr
Fiscal Year January - December

Latest News

Tsakos Energy Navigation: The Preferred Might Be A Better Pick Than The Common

4 days ago · seekingalpha.com

Tsakos Energy Navigation: The Preferred Might Be A Better Pick Than The Common
TEN, Ltd. Announces Common Shares Dividend and Share Repurchase Authorization

7 days ago · globenewswire.com

TEN, Ltd. Announces Common Shares Dividend and Share Repurchase Authorization
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer

8 days ago · gurufocus.com

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer
Sun Pharma Announces UNLOXCYT® (cosibelimab-ipdl) Has Received a Category 2A Preferred Designation in the Updated NCCN Guidelines for Locally Advanced Cutaneous Squamous Cell Carcinoma (laCSCC) Patien

13 days ago · gurufocus.com

Sun Pharma Announces UNLOXCYT® (cosibelimab-ipdl) Has Received a Category 2A Preferred Designation in the Updated NCCN Guidelines for Locally Advanced Cutaneous Squamous Cell Carcinoma (laCSCC) Patien
TEN Hires Versatile Marketing Leader Daniel Incandela as Chief Marketing Officer

26 days ago · businesswire.com

TEN Hires Versatile Marketing Leader Daniel Incandela as Chief Marketing Officer
TEN Ltd. Declares Dividend on its Series F Cumulative Redeemable Perpetual Preferred Shares

28 days ago · globenewswire.com

TEN Ltd. Declares Dividend on its Series F Cumulative Redeemable Perpetual Preferred Shares
Tsakos Energy Navigation Highlights $3.6B Contract Backlog, Tanker Fleet Expansion

1 month ago · marketbeat.com

Tsakos Energy Navigation Highlights $3.6B Contract Backlog, Tanker Fleet Expansion
TEN, Ltd. Continues Its Fleet Renewal and Reports Sale of Panamax Tanker

1 month ago · globenewswire.com

TEN, Ltd. Continues Its Fleet Renewal and Reports Sale of Panamax Tanker
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026

2 months ago · gurufocus.com

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026
TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial

2 months ago · gurufocus.com

TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial

Earnings

Next Earnings
Nov 24, 2026
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
1
Consensus
Hold
Price Target
$65.00
Upside
+23.32%
Buy (0)
Hold (1)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.